The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The ongoing Phase III CELESTIAL-RRCLL trial: sonrotoclax plus anti-CD20 antibody in R/R CLL/SLL
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses the ongoing Phase III CLL-RR1/CELESTIAL-RRCLL trial (NCT06943872), which will investigate sonrotoclax plus anti-CD20 antibody therapies versus venetoclax plus rituximab in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Dr Eichhorst highlights the fourth arm of the study that will allow patients to stop treatment with sonrotoclax earlier if undetectable measurable residual disease (MRD) is achieved. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
